News

The 35th European Society for Clinical Microbiology and Infectious Diseases (ESCMID Global) was held from April 11 to 15 in Vienna, Austria. Regarded as a global leading academic event in the field of infectious diseases and clinical microbiology, it attracted many international top scholars to participate and exchange ideas on topics including drug resistance prevention and control, emerging infectious diseases, and precision diagnosis and treatment. Autobio showcased a range of cutting-edge products at the exhibition and successfully organised the 3rd European Biominds Talks Microbiology Laboratory Testing Conference, facilitating in-depth academic discussions with international experts. For more information, please refer to: 3rd European Biominds Talks

Cutting-edge Achievements Exhibition Expanding International Academic Circle

Autobio's five abstracts were selected for display in the conference poster area, which showcased the latest research results in the field of infectious diseases and clinical microbiology. The selected abstracts focused on MALDI TOF mass spectrometry clinical testing, drug sensitivity testing and other cutting-edge technologies, and covered Autobio's microbiology innovations, practical application cases and clinical experience. These attracted many participants to stop and read. Following the conference, these academic abstracts will be included in the official abstract book, which will serve as a valuable resource for academic research and knowledge sharing.

New Products Unveiled Technical Breakthroughs Attract Attention

Two innovative Autobio products launched at the exhibition attracted a great deal of interest.

The Autof T series represents a breakthrough in microbial identification technology. This fully automated mass spectrometer is the world's smallest of its kind, and its innovative spatial design and technological innovation make it a game-changer in the field. The product employs AIEF and TAA ionization technology, ensuring high sensitivity and resolution even at extremely short flight distances, thus guaranteeing the accuracy of identification results. Its compact design (70% smaller than traditional equipment) saves valuable laboratory space, while its innovative features (e.g. an 85% reduction in required bench space) make it a perfect solution for compact workspaces.The Autof T series is equipped with an 18.5-inch full touch screen and a facial recognition system, facilitating intelligent operation and data security management. The Autof T series carries a database covering more than 1,000 genera and more than 5,200 kinds of pathogenic microorganisms, including featured filamentous fungi and marine aquatic bacteria, which provides a strong support for the detection of complex samples. 

The AutoLumo S900 fully automated immunoassay analyser, with its compact design and highly integrated system, is a new choice for efficient infectious disease detection. The instrument adopts magnetic particle chemiluminescence technology, and can simultaneously detect a variety of infectious disease-related markers such as hepatitis B, hepatitis C, AIDS, etc. The instrument boasts superior sensitivity and specificity, meeting international standards. The AutoLumo S900 is particularly well-suited for small clinics and primary healthcare organisations, offering rapid, reliable results with minimal sample requirements. This capability provides significant benefits for early diagnosis, prevention and control of infectious diseases, especially in remote areas with limited resources. It provides a strong guarantee for early diagnosis and prevention of infectious diseases.

Autobio's innovative products attracted a significant number of attendees to the show. Through interaction and communication with the international business team, visitors gained an in-depth understanding of Autobio's latest technological achievements in the field of microbiology.

Europe's strategic position as a global hub for the medical industry is marked by a strong presence of medical R&D and significant market capacity. The conference provided a platform for the recognition and evaluation of Autobio's innovative ideas and product solutions by European experts and scholars. Looking to the future, Autobio will continue to drive technological innovation, collaborate with global partners to establish a "market community of destiny," and work together to promote the advancement and accessibility of medical laboratory technology. The goal is to contribute to global public health, leveraging the expertise and capabilities of the Chinese medical community.